Vol. 11 No. 1: January-December 2024

Published: 2024-07-31

Original Research Articles

  • Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy

    Chiara Bini, Andrea Marcellusi, Francesco Saverio Mennini, Silvia Ripoli, Laura Fioravanti, Victoria Federico Paly, Alexa Molinari, Paolo Morelli, Stanimira Krotneva, Shujun Li
    248-257
    DOI: https://doi.org/10.33393/grhta.2024.3167

  • A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy

    Marco Bellone, Alice Sabinot, Alessandro D’Arpino, Emanuela Omodeo Salè, Daniela Ghislieri, Lorenzo Pradelli
    239-247
    DOI: https://doi.org/10.33393/grhta.2024.3170

  • Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation model

    Roberto Ravasio, Andrea Marcellusi, Luca De Nicola
    231-238
    DOI: https://doi.org/10.33393/grhta.2024.3309

  • Policy predictive model for better management of chronic obstructive pulmonary disease: economic-organisational implications in the Italian healthcare system

    Debora Antonini, Fausto De Michele, Claudio Micheletto, Dejan Radovanovic, Michele Basile, Eugenio Di Brino, Agostino Fortunato, Valentina Donati, Filippo Rumi
    223-230
    DOI: https://doi.org/10.33393/grhta.2024.3114

  • A cost-effectiveness analysis of Navina Smart on adult patients affected by neurogenic bowel dysfunction

    Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio, Gabriele Righi
    214-222
    DOI: https://doi.org/10.33393/grhta.2024.3168

  • Survival, treatment duration and costs of patients with prostate cancer treated with triptorelin in Italy: a study of administrative databases

    Orazio Caffo, Gaetano Facchini, Luca Degli Esposti, Valentina Acciai, Giorgio Mauri, Paola Mazzanti, Giuseppe Fornarini
    207-213
    DOI: https://doi.org/10.33393/grhta.2024.3055

  • The economic and social burden of congenital thrombotic thrombocytopenic purpura (cTTP) in Italy

    Filippo Rumi, Michele Basile, Eugenio Di Brino, Agostino Fortunato, Debora Antonini
    200-206
    DOI: https://doi.org/10.33393/grhta.2024.3147

  • Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study

    Fiorenzo Santoleri, Paolo Abrate, Laura Pestrin, Enrico Pasut, Germana Modesti, Felice Musicco, Chiara Fulgenzio, Eva Zuzolo, Gabriella Pieri, Martina Roperti, Pietro Gazzola, Marco Gambera, Isabella Martignoni, Valentina Montresor, Francesca Guarino, Laura Grossi, Letizia Di Fabio, Cristina Roberti, Concetta Spoltore, Gabriella Tinari, Stefania De Rosa, Romina Giannini, Roberto Langella, Grazia Mingolla, Mariantonietta Piccoli, Alberto Costantini
    191-199
    DOI: https://doi.org/10.33393/grhta.2024.3204

  • Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney disease

    Chiara Bini, Andrea Marcellusi, Paolo Di Rienzo, Lucia Del Vecchio
    175-190
    DOI: https://doi.org/10.33393/grhta.2024.3062

  • Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel

    Claudio Jommi, Francesca Patarnello, Cosetta Bianchi, Giuliano Buzzetti
    169-174
    DOI: https://doi.org/10.33393/grhta.2024.3107

  • Exploring the administrative burden faced by hematologists: a comprehensive study in Italy

    Davide Petruzzelli, Marco Vignetti, Stefania Trasarti, Paolo Sportoletti, Silvia Della Torre, Roberto Cairoli, Francesca Pia Chiara Leone, Giuseppe Pompilio, Marco Gullì, Eva Brown Hajdukova, Davide Integlia
    161-168
    DOI: https://doi.org/10.33393/grhta.2024.3042

  • Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases

    Cristian Lolli, Antonio Verde, Luca Degli Esposti, Valentina Acciai, Alessia Brigido, Emanuela Proietti, Sarah Scagliarini
    154-160
    DOI: https://doi.org/10.33393/grhta.2024.2892

  • Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women Effective CArdiovascular Risk Evaluation)

    Valentina Perrone, Gerardo Medea, Stefano Urbinati, Diego Sangiorgi, Luca Degli Esposti
    138-147
    DOI: https://doi.org/10.33393/grhta.2024.2731

  • How effective are prescriptive governance tools? Results from the application of AIFA notes

    Giaele Moretti, Benedetta Dal Canto, Francesco Attanasio, Alma Martelli, Francesca Ferrè
    131-137
    DOI: https://doi.org/10.33393/grhta.2024.3027

  • Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders

    Alicia Gil, María Reyes Abad, Carmen Alerany, Laia Alsina, Eduardo López Granados, Olaf Neth, José Luis Poveda, Jacques G. Rivière, Carlos Rodríguez-Gallego, Joanne B. Tutein Nolthenius, Raquel Figueiredo , Silvia Subías Labazuy
    124-130
    DOI: https://doi.org/10.33393/grhta.2024.3041

  • The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health Service

    Claudio Jommi, Federico Pantellini, Giovanni Giuliani, Marianna Cavazza
    115-123
    DOI: https://doi.org/10.33393/grhta.2024.2735

  • Regional administrative data and their role in planning, programming and controlling at regional level

    Irene Marzona, Paolo Stella, Gianluca Trifirò, Giovanni Corrao
    101-104
    DOI: https://doi.org/10.33393/grhta.2024.3024

  • Heart failure and economic impact: an analysis in real clinical practice in Italy

    Melania Dovizio, Melania Leogrande, Luca Degli Esposti
    94-100
    DOI: https://doi.org/10.33393/grhta.2024.3013

  • The socioeconomic burden of adult attention-deficit/hyperactivity disorder in Spain

    Maria Merino, Paulina Maravilla-Herrera, Teresa Martín Lorenzo, Juan Antonio Arance, Julio Bobes, Montse Corrales, Fátima Guzmán, María Morales, Carlos Mur
    82-93
    DOI: https://doi.org/10.33393/grhta.2024.2697

  • Regional Formularies in Italy: current state and future perspectives

    Alberto Bortolami, Claudio Jommi, Filippo Bresciani, Luca Piccoli, Elisa Sangiorgi, Giovanna Scroccaro
    68-74
    DOI: https://doi.org/10.33393/grhta.2024.2677

  • Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis

    Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio
    55-67
    DOI: https://doi.org/10.33393/grhta.2024.2658

  • Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

    Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio
    38-50
    DOI: https://doi.org/10.33393/grhta.2024.2728

  • Clinical and economic burden of peristomal skin complications: Activity Based Costing analysis

    Agostino Fortunato, Filippo Rumi, Massimo Zazzetta, Marco Della Valle, Vincenzo Pedace, Americo Cicchetti
    31-37
    DOI: https://doi.org/10.33393/grhta.2024.2639

  • Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)

    Silvia Calabria, Manenti Lucio, Giulia Ronconi, Carlo Piccinni, Leonardo Dondi, Letizia Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, Nello Martini
    22-30
    DOI: https://doi.org/10.33393/grhta.2024.2696

  • A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

    Michele Basile, Ilaria Valentini, Roberto Attanasio, Renato Cozzi, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Renata Simona Auriemma, Ernesto De Menis, Felice Esposito, Emanuele Ferrante, Giuseppe Iatì, Diego Mazzatenta, Maurizio Poggi, Roberta Rudà, Fabio Tortora, Fabio Cruciani, Zuzana Mitrova, Rosella Saulle, Simona Vecchi, Paolo Cappabianca, Agostino Paoletta, Alessandro Bozzao, Marco Caputo, Francesco Doglietto, Francesco Ferraù, Andrea Gerardo Lania, Stefano Laureti, Stefano Lello, Davide Locatelli, Pietro Maffei, Giuseppe Minniti, Alessandro Peri, Chiara Ruini, Fabio Settanni, Antonio Silvani, Nadia Veronese, Franco Grimaldi, Enrico Papini, Americo Cicchetti
    1-16
    DOI: https://doi.org/10.33393/grhta.2024.2601

Point of View

  • Early access programs for medicines: a reform proposal for the Italian National Health Service

    Patrizia Popoli, Giovanni Giuliani, Arturo Cavaliere, Claudio Jommi
    148-153
    DOI: https://doi.org/10.33393/grhta.2024.3098

  • The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example

    Mickaël Hiligsmann, Olivier Bruyère
    75-81
    DOI: https://doi.org/10.33393/grhta.2024.2682

  • HTA regulation: how is Italy moving?

    Francesca Patarnello
    51-54
    DOI: https://doi.org/10.33393/grhta.2024.3025

  • The future of drugs distribution in the National Health System

    Massimo Medaglia, Giuliano Buzzetti, Marco Cossolo, Paola Deambrosis, Giovanna Scroccaro
    17-21
    DOI: https://doi.org/10.33393/grhta.2024.2619

Short Communication

  • Patient-reported outcomes in epilepsy: a case study exploring their usage and impact

    Simona Lattanzi, Angela La Neve
    108-114
    DOI: https://doi.org/10.33393/grhta.2024.3020

  • Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy

    Andrea Messori, Maria Rita Romeo, Valeria Fadda, Francesca Collini, Sabrina Trippoli
    105-107
    DOI: https://doi.org/10.33393/grhta.2024.3018